argus

Zydus Lifesciences Limited

NSE: ZYDUSLIFEINE010B010271,16,114 Cr

Timeline

Time (IST)TypeMEventSrc
14 Nov, 01:45 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
14 Nov, 01:42 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 14, 2025, titled "Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial".nse
13 Nov, 07:03 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
13 Nov, 07:01 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Closure of USFDA inspection at Zydus oncology injectable manufacturing facility in SEZ1, Ahmedabad".nse
13 Nov, 04:44 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
13 Nov, 04:43 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Revised press release".nse
13 Nov, 01:56 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
13 Nov, 01:54 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg".nse
13 Nov, 12:43 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
13 Nov, 12:41 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Zydus Amplitude receives CE mark for its robotic surgical system Andy .nse
13 Nov, 11:19 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
13 Nov, 11:16 amZydus Lifesciences Limited has informed the Exchange about Transcriptnse
11 Nov, 09:56 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
11 Nov, 09:53 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Zydus receives approval from China s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg".nse
07 Nov, 06:01 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
07 Nov, 05:59 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 07, 2025, titled "Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg".nse
06 Nov, 06:56 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
06 Nov, 06:55 pmZydus Lifesciences Limited has informed the Exchange about Link of Recordingnse
06 Nov, 01:20 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
06 Nov, 01:19 pmZydus Lifesciences Limited has informed the Exchange about Investor Presentationnse
06 Nov, 01:14 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
06 Nov, 01:12 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Raising of Fundsbse
06 Nov, 01:09 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2025, titled "Financial Performance for Q2 & H1 FY26".nse
06 Nov, 01:04 pmZydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on November 06, 2025.nse
06 Nov, 01:03 pmZydus Lifesciences Ltd - 532321 - Unaudited Financial Results For The Quarter And Half Year Ended On September 30, 2025bse
06 Nov, 01:03 pmZydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.nse
06 Nov, 09:55 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
06 Nov, 09:52 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2025, titled "Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of beta-thalassemia".nse
05 Nov, 11:16 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
05 Nov, 11:13 amZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Zydus receives EIR for SEZ II manufacturing facility, Ahmedabad".nse
04 Nov, 02:39 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
04 Nov, 02:36 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Zydus receives tentative approval from USFDA for Budesonide delayed release capsules, 4 mg".nse
03 Nov, 05:27 pmZydus Lifesciences Ltd - 532321 - Update on board meetingbse
01 Nov, 11:09 amZydus Lifesciences Limited has informed the Exchange about General Updatesnse
01 Nov, 11:06 amZydus Lifesciences Ltd - 532321 - Demand Notice From GST Departmentbse
29 Oct, 06:28 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
29 Oct, 06:26 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated October 29, 2025, titled "Zydus receives EIR for the Baddi manufacturing facility".nse
29 Oct, 12:23 pmZydus Lifesciences Ltd - 532321 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter / Half Year Ended On September 30, 2025.bse
26 Oct, 11:54 amZydus Lifesciences Limited has informed the Exchange about General Updatesnse
26 Oct, 11:51 amZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Acquisitionbse
24 Oct, 07:25 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
24 Oct, 07:23 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated October 24, 2025, titled "Press Release".nse
17 Oct, 11:22 amZydus Lifesciences Limited has informed the Exchange about General Updatesnse
17 Oct, 11:19 amZydus Lifesciences Ltd - 532321 - Updatebse
06 Oct, 04:25 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
06 Oct, 04:22 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated October 06, 2025, titled "Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg".nse
06 Oct, 03:04 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
06 Oct, 03:02 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated October 06, 2025, titled "Zydus receives final approval from USFDA for Deflazacort oral suspension, 22.75 mg/mL".nse
01 Oct, 05:52 pmZydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
01 Oct, 05:49 pmZydus Lifesciences Limited has informed the Exchange regarding a press release dated October 01, 2025, titled "Sentynl Therapeutics updates on its NDA for CUTX-101".nse